{"text":"This work was supported by the EPSRC (EP/C51933/01, EP/J008052/1 and EP/C013956/1), the EC project Q-ESSENCE (248095), the Royal Society, the AFOSR EOARD, The Australian Research Council's Federation Fellow program (FF0668810), Centre for Engineered Quantum Systems (CE110001013) and the Centre for Quantum Computation and Communication Technology (CE110001027). J. B. S. acknowledges support from the United States Air Force Institute of Technology. X.-M. J. and N. K. L. are supported by EC Marie Curie Fellowships (PIIF-GA-2011-300820 and PIEF-GA-2010-275103). M. B. is supported by a FASTQUAST ITN Marie Curie fellowship.","id":"WOS:000316614600026"}
{"text":"This work was supported by MICINN (Spain), Comunitat Autonoma de les Illes Balears, FEDER, and the European Commission under Projects TEC2009-14101 (DeCoDicA), Grups Competitius and EC FP7 Projects PHOCUS (Grant No. 240763) and NOVALIS (Grant no. 275840).","id":"WOS:000316614600034"}
{"text":"We acknowledge invaluable support from V. Pillard and S. Eimer for the film preparation, L. Santandrea for the finite-element simulations and fruitful discussions with E. Fullerton, Edwin Fohtung and Oleg Sphyrko. This work was partially supported by the European Communities FP7 programme, through contract NAMASTE number 214499 and contract MAGWIRE number 257707, and the ANR-NSF project Friends. N. L. also acknowledges financial support from C'Nano IDF.","id":"WOS:000316614600048"}
{"text":"This work was supported by the Flemish Fund for Scientific research (FWO Vlaanderen) by research grants no. G.0700.10N (to K. D. R) and FWO11/PDO/046 (to M. M.), a research grant from the Geconcentreerde Onderzoeksactie (GOA) of Ghent University (BOF09/GOA/005), a grant from the Multidisciplinary Research Partnership (MRP) 'Biotechnology for a Sustainable Economy' no. 01MRA510W (BOF/MRP/005), EU-FP7 Biotreat project (Contract number 266039; call FP7-KBBE-2010.3.5.01) and Inter-University Attraction Pole (IUAP) 'mu-manager' funded by the Belgian Science Policy (BELSPO, P7/25). The support of the EU project ULIXES (GA 266473) is acknowledged for the discussion of the conceptual aspects of the study. We would like to thank Tim Lacoere for the graphical design of Fig 3.","id":"WOS:000316614600053"}
{"text":"We are indebted to P. Simon, C. Bergenfeldt, P. Samuelsson, C. Mora, K. Le Hur and G. Zarand for fruitful discussions. The devices have been made within the consortium Salle Blanche Paris Centre. This work is supported by the ANR contracts DOCFLUC, HYFONT, SPINLOC and the EU-FP7 project SE2ND[271554].","id":"WOS:000316614600070"}
{"text":"We are greatly indebted to the following people who kindly provided us the plasmids used in this manuscript: Johan de Rooij, Hubrecht Institute, Utrecht (vinculin-GFP); Anna Huttenlocher, University of Wisconsin, Madison, WI (talin-GFP); Klemens Rottner, Institut fur Genetik, Bonn (zyxin-GFP); Michelle Digman, University of California, Irvine, CA (paxillin-GFP); Michael Sixt, Max Planck Institute of Biochemistry, Martinsried (Lifeact-GFP and -RFP); Martin Schwartz, Yale School of Medicine, New Haven, CT (VinTS and VinTL). The authors thank the Microscopic Imaging Center of the Nijmegen Centre for Molecular Life Sciences for use of their facilities and Jack Fransen for critically reading the manuscript. This research was supported by EU grants BIO-LIGHT-TOUCH (028781) and Immunanomap (MRTN-CT-2006-035946) and EU-Mexico FONCICYT (C002-2008-1 ALA/127249) awarded to C. G. F., and by a Young investigator Grant from the Human Frontier Science Program (RGY0074/2008) to A. C. M. M. is supported by the REMEDI (HEALTH-F5-2009-242276) grant. The research leading to these results has received funding also from the European Commission's Seventh Framework Programme (FP7-ICT-2011-7) under grant agreement no. 288263 (NanoVista). A. C. is the recipient of a Meervoud grant (836.09.002) and C. G. F. was awarded with a Spinoza prize, both from The Netherlands Organisation for Scientific Research (NWO).","id":"WOS:000316614600082"}
{"text":"We acknowledge theoretical assistance of Pavel Motloch and support from EU ERC Advanced Grant No. 268066 and FP7-215368 SemiSpinNet, the Ministry of Education of the Czech Republic Grants No. LM2011026, the Grant Agency of the Czech Republic Grant No. 202/09/H041 and P204/12/0853, the Charles University in Prague Grant No. SVV-2012-265306 and 443011, the Academy of Sciences of the Czech Republic Preamium Academiae and US grants ONR-N000141110780, NSF-MRSEC DMR-0820414, NSF-DMR-1105512.","id":"WOS:000316614600091"}
{"text":"The work in the authors' laboratory is supported by operating grants and a group grant from the Canadian Institutes for Health Research, as well as by the Canadian Foundation for Innovation. P.K. is an Alberta Heritage Foundation for Medical Research (AIHS) Scientist and the Snyder Chair in Critical Care Medicine. E.K. is supported by an FP7-PEOPLE-2010-IOF grant (No. 273340) from the European Union.","id":"WOS:000316616100009"}
{"text":"This work was partially supported by the French ANR P3N DELIGHT, ANR JCJC MIND, the ERC starting grant 277885 QD-CQED, the French RENATECH network and the CHISTERA project SSQN. O.G. acknowledges support by the French Delegation Generale de l'Armement.","id":"WOS:000316616400001"}
{"text":"This work was supported by the European Research Council to J.J.vT. via grant agreement no. 208650, and the EPSRC via award EP/I003304/1. This work was supported by the National Science Foundation to J.T.S. and P.C. via award CHE-1026369.","id":"WOS:000316616400031"}
{"text":"Wellcome Trust (grant numbers WT077044/Z/05/Z); BBSRC Bioinformatics and Biological Resources Fund (grant numbers BB/F010435/1); Howard Hughes Medical Institute (to G. C., J.C., S. R. E and R. D. F.); Stockholm University, Royal Institute of Technology and the Swedish Natural Sciences Research Council (to K. F. and E. L. L. S.) and Systems, Web and Database administration teams at Wellcome Trust Sanger Institute (WTSI) (infrastructure support). Funding for open access charge: Wellcome Trust (grant numbers WT077044/Z/05/Z); BBSRC Bioinformatics and Biological Resources Fund (grant numbers BB/F010435/1).","id":"WOS:000298601300043"}
{"text":"This work was funded by a Wellcome Trust Senior Research Fellowship to DvA (WT087590MA) and an MRC Programme Grant (G0900138) to DvA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","id":"WOS:000300767100003"}
{"text":"The resarch was supported by Wellcome Trust Grant 082273/Z/07/Z (to S.P.B.), American Heart Association's postdoctoral fellowship (to S.M.E.), and Fundacao para a Ciencia e Tecnologia, Portugal, SFRH/BD/33856/2009 (to S.E.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","id":"WOS:000305695100018"}
{"text":"This work was made possible by a Wellcome Trust Msc Fellowship awarded to EWB (#090569/Z/09/Z) and a Wellcome Trust Senior Fellowship awarded to ME (#076827). The KEMRI Wellcome-Trust programme is supported by core funding from Wellcome-Trust (#092654/Z/10/A). The funders had no role in the design, conduct, analyses or writing of this study or in the decision to submit for publication.","id":"WOS:000305946200011"}
{"text":"The Swiss Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) was supported by the Swiss National Science Foundation (grants no 33CS30_134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099, 3233-054996, PDFMP3-123171), the Federal Office for Forest, Environment and Landscape, the Federal Office of Public Health, the Federal Office of Roads and Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, Zurich, the Swiss Lung League, the canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, Valais and Zurich, Schweizerische Unfallversicherungsanstalt (SUVA), Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, and Abbott Diagnostics. Genotyping in the GABRIEL framework was supported by grants European Commission 018996 and Wellcome Trust WT 084703MA. Identification of pathways was supported by the French National Research Agency (Bio2nea project ANR-CES 2009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.I have read the journal's policy and have the following conflicts: The SAPALDIA study was supported by the UBS Wealth Foundation, Talecris Biotherapeutics GmbH, and Abbott Diagnostics in terms of unrestricted grants for personnel and genotyping. The support of these institutions did not influence the scientific work regarding study design, data collection, data analysis, interpretation of results, decision to publish, or preparation of the manuscript in any way. Also, this does not alter our adherence to all the PLoS ONE policies on sharing data and materials.","id":"WOS:000306461800046"}
{"text":"\"This meta-analysis is a collaborative effort involving data from many individual studies and many sources of funding. The details of funding sources for each study are detailed in Text S1 as well as below. Framingham Heart Study (FHS): The phenotype-genotype association analyses were funded through grants from the NIA R21AG032598 (JM Murabito, KL Lunetta), R01HL094755 (AD Coviello, RS Vasan, S Bandinelli), and R01AG31206 (RS Vasan, S Bandinelli), R01 AR/AG 41398 (DP Kiel). This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II), funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Gothenburg Osteoporosis and Obesity Determinants (GOOD) Study: Financial support was received from the Swedish Research Council (K2010-54X-09894-19-3, 2006-3832, and K2010-52X-20229-05-3), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Soderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Vastra Gotaland Foundation, the Goteborg Medical Society, the Novo Nordisk foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to acknowledge Maria Nethander at the genomics core facility at University of Gothenburg for statistical analyses. We would also like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and #01 IG 07015 G for access to their grid resources. We would also like to thank Karol Estrada, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, for advice regarding the grid resources. Health, Aging, and Body Composition (Health ABC) Study: This Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was also supported in part by the Intramural Research Program of the National Institute on Aging, NIH, Bethesda, Maryland. Invecchiare in Chianti (InCHIANTI): The InCHIANTI study baseline (1998-2000) was supported as a \"\"targeted project'' (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI Follow-up 1 (2001-2003) was funded by the U.S.National Institute on Aging (Contracts: N.1-AG-1-1 and N.1-AG-1-2111); the InCHIANTI Follow-ups 2 and 3 studies (2004-2010) were financed by the U.S. National Institute on Aging (Contract: N01-AG-5-0002), supported in part by the Intramural research program of the National Institute on Aging, National Institutes of Health, Baltimore, Maryland. JRB Perry is a Sir Henry Wellcome Postdoctoral Research Fellow (092447/Z/10/Z). Cooperative Health Research in the Region of Augsburg (KORA): The KORA research platform was initiated and financed by the Helmholtz Zentrum Munich, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Part of this work was financed by the German National Genome Research Network (NGFN-2 and NGFNPlus: 01GS0823). Our research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. Multi-Ethnic Study of Atherosclerosis (MESA): MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is provided by grants and contracts N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156. Funding support for the sex hormone dataset was provided by grants HL074406 and HL074338. Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-6-4278. Genotyping was performed at the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) and at Affymetrix (Santa Clara, California, USA) using the Affymetric Genome-Wide Human SNP Array 6.0. Northern Finland Birth Cohort 1966 Study (NFBC-66): NFBC1966 received financial support from the Academy of Finland (project grants 104781, 120315, 129269, 1114194, Center of Excellence in Complex Disease Genetics, and SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643), NHLBI grant 5R01HL087679-02 through the STAMPEED program(1RL1MH083268-01), NIH/NIMH (5R01MH63706: 02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, the Medical Research Council UK (G0500539, G0600705, PrevMetSyn/SALVE), and the Wellcome Trust (project grant GR069224). We acknowledge the support of U.S. National Heart, Lung, and Blood Institute grant HL087679 through the STAMPEED program; grants MH083268, GM053275-14, and U54 RR020278 from the U.S. National Institutes of Health; grant DMS-0239427 from the National Science Foundation; the Medical Research Council of the UK, EURO-BLCS, QLG1-CT-2000-01643 and the European Community's Seventh Framework Programme (FP7/2007-2013); ENGAGE project and grant agreement HEALTH-F4-2007-201413. The authors would like to thank the Center of Excellence in Common Disease Genetics of the Academy of Finland and Nordic Center of Excellence in Disease Genetics, the Sydantautisaatio (Finnish Foundation of Heart Diseases), the Broad Genotyping Center, D. Mirel, H. Hobbs, J. DeYoung, P. Rantakallio, M. Koiranen, and M. Isohanni for advice and assistance. Rotterdam study (RS1): The generation and management of GWAS genotype data for the Rotterdam Study are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012).This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810, and funding from the European Commision (HEALTH-F2-2008-201865, GEFOS; HEALTH-F2-2008-35627, TREAT-OA). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture, and Science; the Ministry for Health, Welfare, and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. We thank Pascal Arp, Mila Jhamai, Dr. Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. We would like to thank Dr. Tobias A. Knoch, Karol Estrada, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and #01 IG 07015 G for access to their grid resources. Study of Health in Pomerania (SHIP): SHIP is part of the Community Medicine Research Net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), and the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg, West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg, West Pomerania. The University of Greifswald is a member of the \"\"Center of Knowledge Interchange'' program of the Siemens AG. This work is also part of the research project Greifswald Approach to Individualized Medicine (GANI_MED). The GANI_MED consortium is funded by the Federal Ministry of Education and Research and the Ministry of Cultural Affairs of the Federal State of Mecklenburg, West Pomerania (03IS2061A). The SHBG reagents used were sponsored by Siemens Healthcare Diagnostics, Eschborn, formerly DPC Biermann GmbH, Bad Nauheim, Germany. Novo Nordisk provided partial grant support for the determination of serum samples and data analysis. R Haring received honorarium for lectures by Bayer Pharma AG. H Wallaschofski has received research grants from Novo Nordisk and Pfizer for research unrelated to the contents of this manuscript and honorarium for lectures by Bayer Pharma AG. TWINS UK: The study was funded by the Wellcome Trust, European Community's Seventh Framework Programme (FP7/2007-2013) grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. TD Spector is an NIHR senior Investigator.The project also received support from a Biotechnology and Biological Sciences Research Council (BBSRC) project grant (G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (PI: Terri Young). We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control, and genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Genotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant. The Cardiovascular Risk in Young Finns Study (YFS): The Young Finns Study has been financially supported by the Academy of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere, and Turku University Hospital Medical Funds (grant 9M048 for 9N035 for TeLeht); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation; Tampere Tuberculosis Foundation; and Emil Aaltonen Foundation (T Lehtimaki). The expert technical assistance in the statistical analyses by Irina Lisinen and Ville Aalto are gratefully acknowledged. Women's Health Initiative (WHI): Genotyping was performed at the Broad Institute (Cambridge, MA) through the NHGRI-funded Genomics and Randomized Clinical Network (U01 HG005152) or GARNET. The WHI programis funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 4210726, 42129-32, and 44221. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A listing of WHI investigators can be found at http://www.whiscience.org/publications/WHI_investigators_shortlist.pdf. Coronary Artery Risk Development in Young Adults (CARDIA) Women's Study: The CARDIA study is funded by contracts N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205, and N01-HC-45204 and by the CARDIA Women's study by R01-HL065611 from the National Heart, Lung, and Blood Institute to the CARDIA investigators. Genotyping of the CARDIA participants was supported by grants U01-HG-004729, U01-HG-004446, and U01-HG-004424 from the National Human Genome Research Institute. Statistical analyses were supported by grants U01-HG-004729 and R01-HL-084099 to M Fornage. M Wellons is supported by the Career Development Award 5-K23-HL087114. European Prospective Investigation into Cancer and Nutrition (Prospect-EPIC): The Prospect-EPIC study was funded by \"\"Europe against Cancer'' Programme of the European Commission (SANCO); the Dutch Ministry of Health, Welfare, and Sports (VWS); and ZONMw.Osteoporotic fractures in men (MrOS) study Sweden: Financial support was received from the Swedish Research Council (2006-3832), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Soderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Vastra Gotaland Foundation, the Goteborg Medical Society, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. Nurses' Health Study (NHS): The NHS breast cancer GWAS was performed as part of the Cancer Genetic Markers of Susceptibility (CGEMS) initiative of the NCI. We particularly acknowledge the contributions of R. Hoover, A. Hutchinson, K. Jacobs and G. Thomas. The current research is supported by CA87969, CA49449, CA40356, CA128034, and U01-CA98233 from the National Cancer Institute. We acknowledge the study participants in the NHS for their contribution in making this study possible. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"","id":"WOS:000306840400020"}
{"text":"Work in the laboratory of J.K. has been supported by the Wellcome Trust (074318 and 075491/Z/04 to core facilities Wellcome Trust Centre for Human Genetics), the European Research Council (ERC) under European Commission 7th Framework Programme (FP7/2007-2013)/ERC grant agreement No. 281824, the Medical Research Council (98082), and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre.","id":"WOS:000314744400005"}
{"text":"This work was supported by the RAPIDD program of the Science and Technology Directorate, U.S. Department of Homeland Security, and the Fogarty International Center, NIH. SR was also funded by: the NIH Fogarty Center (R01 TW008246-01), the Wellcome Trust (University Award 093488/Z/10/Z), The Medical Research Council (UK, Project Grant MR/J008761/1) and European Union Seventh Framework Programme (FP7/2007-2013, Grant Agreement no278433-PREDEMICS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","id":"WOS:000315157200118"}
{"text":"We acknowledge support from a Wellcome Trust Programme Grant award: PK-PD modelling to optimize treatment for HIV, TB and malaria. (ref 083851/Z/07/Z).M.L. and P.B. are supported by European and Developing Countries Clinical Trials Partnership grants (TA.09.40200.020 and TA.11.40200.047).Transparency Declaration: D.J.B. and S.H.K. have received research funding for development of the web site www.hiv-druginteractions.org from Viiv, BMS, Gilead, Janssen, Merck, Boehringer-Ingelheim. DJB has received honoria for lectures or Advisory Boards from Viiv, BMS, Gilead, Janssen, Merck.M.L. has received grants from Janssen and is supported by the Sewankambo scholarship at IDI which is funded by Gilead Foundation.","id":"WOS:000315524700001"}
{"text":"The current study is funded by grants from the South-Eastern Norway Regional Health Authority, the Research Council of Norway, the Odd Fellow MS society, the Danish Multiple Sclerosis Society, the Swedish Medical Research Council, the AFA foundation, Knut and Alice and Wallenbergs foundations and Council for Working Life and Social Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.We thank all patients and healthy controls for their participation. The International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium2 provided the genotypes used in the screening phase of this study. We acknowledge the collaboration and principal funding for the genome-wide study provided by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium2 project (085475/B/08/Z and 085475/Z/08/Z). We thank all contributors to the collection of samples and clinical data in the Norwegian MS Registry and Biobank. The Norwegian Bone Marrow Donor Registry, Rikshospitalet, Oslo University Hospital are acknowledged for providing Norwegian controls. The Centre for Integrative Genetics; CIGENE, Norwegian University of Life Sciences (UMB) Aas is thanked for performing Sequenom analyses.","id":"WOS:000315637900131"}
{"text":"ACKNOWLEDGMENT The authors gratefully acknowledge the financial support of the Dutch Technology Foundation (STW) under project No. 10414.","id":"50|narcis______::0b552824e655d0cd2251691e1722aa20"}
{"text":"References This research was supported by the National Institutes of Health/National Heart, Lung and Blood Institute grants contracts R01-HL-60700, R01-HL-54776 and N01-HC-25195 Bethesda, MD. Conflict of Interest : The authors have no conflict of interest. Abraham S Johnson CL Najjar MF 1979 Weight and height of adults 18–74 years of age. United States, 1971–1974 Vital Health Stat 11 211 1 49 473616", "id":"50|od_______908::08e1f7cb9848aea02be6b2ab8b4dc88d"}
{"text":"This work was supported by the Ministry of Science, Republic of Serbia, grants ON175069, ON175071 and ON175103; and Faculty of Medical Science, junior project number 24/10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript", "id":"50|od_______908::9196de8e0cdb0e9973c3ee27f99f0243"}
{"text":"SA was supported in part by NIH R01GM073822 (to Justin Borevitz). ES was supported in part by a Lise Meitner award from the Austrian Science Foundation (FWF M1420-B21).", "id":"50|od_______908::0e6fdb767c342f227e2df4aba1f6932f"}
{"text":"This work was supported by the Swiss National Foundation for Scientific Research under grant No. 620-62868.00.", "id":"50|od________18::9c0bd6884a356d26618ade8507fdb40a"}
{"text":"This work was funded by a Wellcome Trust Senior Research Fellowship to DvA (WT123456789MA)", "id":"50|pub_______00::with_wt_unidentified_reference"}
{"text":"This work was supported by the STFC Grant ST/J000469/1, “String theory, gauge theory & duality”.", "id":"50|od________18::6e336f58fbfcea76362597f026d6a68c"}
{"text":" Besides expeditions such as Tara Oceans, Malaspina, and others, marine biology stations such as Woods Hole, Roscoff, and Villefranche, for example, should return to the fore.", "id":"PMC3386204"}
{"text":"In-group sampling included specimens collected from various stations of Tara expedition and also from other regional missions", "id":"PMC3625178"}
{"text":"Data provision by national hydrometeorological services, the FP7 DROUGHT-R&SPI project (Fostering European Drought Research and Science-Policy Interfacing, grant, 282769) and funding from the EC post-grant Open Access Pilot (OpenAIRE2020 project (H2020-EINFRA-2014-1, 643410) for covering most of the Open Access fee and ACRP (project B464822) was highly appreciated.", "id":"wurpubs-381553"}
{"text":"This work was supported by FONDECYT#1120074, Santiago, Chile.", "id":"50|od_______908::1c15a8bbfa79b74d1d36476ada14fc2f"}
{"text":"This research was funded by the US National Institutes of Health (grant #U41HG006623 and #GM103504) and Scientific and Technological Research Council of Turkey (grant #111E036).", "id":"50|od_______908::6118d84402bac3159990bd741cdd0fe2"}
{"text":"This work has been supported by grant MTM2012-31073 (Ministerio de Econom´ıa y Competitividad, Spain) and the James S. McDonnell Foundation (USA) through the 21st Century Science Initiative in Mathematical & Complex Systems Approaches for Brain Cancer-Pilot Award 220020351.", "id":"50|od________18::7b73b2f9431d0f7dbcf1867532d6554b"}
{"text":"Funding Information My research was supported by the Academy of Finland (grants #129662 and #134728).", "id":"50|od_______908::06173645b3548760065d4a797ca6d23a"}
{"text":"This work was supported by grants from the General Secretariat of Research and Technology of Greece (GSRT) SINERGASIA “THERACAN” 11SYN-1-485 and KRIPIS “STHENOS” MIS 447985.", "id":"50|dedup_wf_001::92685f7e22342478a67376985a967618"}
{"text":"G. Verzini is partially supported by the PRIN-2015KB9WPT Grant: “Variational methods, with applications to problems in mathematical physics and geometry”.", "id":"50|od________18::9580de872794f07653f436e1ba51007f"}
{"text":"Cirici would like to acknowledge financial support from the DFG (SPP-1786) and AGAUR (Beatriu de Pinós Program) and partial support from the AEI/FEDER, UE (MTM2016-76453-C2-2-P).", "id":"50|od________18::52fbb77464f6ed2751a26bfc3bf307bf"}